Dr. Edward M. Wolin

Dr. Edward M. Wolin, MD, is a world-recognized expert in neuroendocrine tumor (NET) care and currently serves as Director of the Center for Carcinoid and Neuroendocrine Tumors at The Mount Sinai Hospital. He is also Professor of Medicine in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai. Dr. Wolin earned his medical degree from the University of Connecticut School of Medicine and completed his residency in internal medicine at Yale-New Haven Hospital, followed by a medical oncology fellowship at Stanford University. Board-certified in internal medicine and medical oncology, he offers comprehensive care to patients with neuroendocrine tumors, carcinoid tumors, and other gastrointestinal malignancies.

A nationally prominent clinical researcher, Dr. Wolin has been instrumental in developing novel therapies for NETs, including the use of somatostatin analogs, targeted agents, peptide receptor radionuclide therapy (PRRT), and immunotherapy strategies. His translational research investigates tumor biomarkers, imaging techniques, and mechanisms of therapeutic resistance in neuroendocrine cancers. He has led and contributed to numerous clinical trials and has authored over 150 peer-reviewed publications, book chapters, and national treatment guidelines. Dr. Wolin is a frequent speaker at international oncology and endocrinology symposia and has received recognition for his contributions to improving NET outcomes.

In addition to his clinical and scientific leadership, Dr. Wolin is a strong advocate for patient education and empowerment, collaborating closely with national organizations to promote early detection and awareness of neuroendocrine tumors. He mentors fellows and junior faculty and plays an active role in shaping future innovations in rare cancer care. Through his deep commitment to multidisciplinary collaboration, evidence-based medicine, and personalized treatment, Dr. Wolin continues to be a driving force in advancing the standard of care for patients with neuroendocrine and carcinoid tumors.